3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1
4
Phase 4
2
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
438
Neoplasms
363
Breast Neoplasms
260
Colorectal Neoplasms
243
Neoplasm Metastasis
213
Melanoma
209
Leukemia, Myeloid, Acute
188
Multiple Myeloma
187
Pancreatic Neoplasms
181
Ovarian Neoplasms
178
Recurrence
173
Prostatic Neoplasms
161
Lymphoma, Non-Hodgkin
142
Stomach Neoplasms
133
Squamous Cell Carcinoma of Head and Neck
127
Lung Neoplasms
125
Lymphoma
121
Carcinoma, Hepatocellular
117
Carcinoma, Renal Cell
102
Triple Negative Breast Neoplasms
100
Leukemia, Lymphocytic, Chronic, B-Cell
99
Glioblastoma
97
Leukemia
93
Advanced Solid Tumor
92
Small Cell Lung Carcinoma
91
Lymphoma, Large B-Cell, Diffuse
90
Head and Neck Neoplasms
87
Advanced Solid Tumors
84
Endometrial Neoplasms
79
Myelodysplastic Syndromes
78
Interventions
pembrolizumab
1
olaparib
1
lenvatinib
1
enzalutamide
1
belzutifan
1
Prednisone
1
Etoposide
1
Docetaxel
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
INDUSTRY
×
Metastatic Castration-Resistant Prostate Cancer
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled